Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL323763 | 0.83 | SMPD1 (0.44) | SMPD1 | |
| SCHEMBL19510957 | 0.82 | NPC1 (0.41) | POLBNPC1RAB9ATDP1 | |
| SCHEMBL21383849 | 0.80 | NPC1 (0.35) | POLBNPC1RAB9ATDP1SMPD1 | |
| SCHEMBL21383851 | 0.80 | SMPD1 (0.40) | POLBNPC1RAB9ATDP1SMPD1 | |
| SCHEMBL19511127 | 0.77 | SMPD1 (0.38) | POLBNPC1RAB9ATDP1SMPD1 | |
| SCHEMBL17122452 | 0.77 | SMPD1 (0.43) | SMPD1 | |
| SCHEMBL21383844 | 0.73 | RAB9A (0.50) | POLBNPC1RAB9ASMPD1HSP90AA1 | |
| SCHEMBL1941686 | 0.73 | KMT2A (0.51) | POLBNPC1RAB9ATDP1MEN1 | |
| SCHEMBL20668700 | 0.68 | MRGPRX4 (0.40) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL21384116 | 0.67 | NPC1 (0.33) | NPC1RAB9ATDP1SMPD1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| EP-3768294-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | Carmot Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2019183577-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | POLB 4729/4885NPC1 1890/4885RAB9A 664/4885 |
| US-11535660-B1 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | POLB 4782/4885NPC1 1936/4885RAB9A 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.